Sandbox Reserved 390: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
<Structure load='3qx3' size='500' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /><!-- PLEASE DO NOT DELETE THIS TEMPLATE --> | <Structure load='3qx3' size='500' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /><!-- PLEASE DO NOT DELETE THIS TEMPLATE --> | ||
Crystal structure of a large fragment of human type II topoisomerases (TOP2) complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex<ref>PMID: 21778401</ref>. The interplay | Crystal structure of a large fragment of human type II topoisomerases (TOP2) complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex<ref>PMID: 21778401</ref>. The interplay between the <scene name='Sandbox_Reserved_390/Top/6'>protein</scene>, the <scene name='Sandbox_Reserved_390/Top/5'>DNA</scene>, and the drug explains the structure-activity relations of etoposide derivatives and the molecular basis of drug-resistant mutations. Also, at the <scene name='Sandbox_Reserved_390/Top/1'>active site</scene> we can see how the <scene name='Sandbox_Reserved_390/Top/7'>ligand</scene>, the <scene name='Sandbox_Reserved_390/Top/3'>alpha helices</scene>, and the <scene name='Sandbox_Reserved_390/Top/2'>beta sheets</scene> interact. | ||
<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | <!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | ||
==References== | ==References== | ||
<references /> | <references /> | ||
Revision as of 15:42, 19 September 2012
Human topoisomerase IIbeta in complex with DNA and etoposide
|
Crystal structure of a large fragment of human type II topoisomerases (TOP2) complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex[1]. The interplay between the protein, the DNA, and the drug explains the structure-activity relations of etoposide derivatives and the molecular basis of drug-resistant mutations. Also, at the active site we can see how the ligand, the alpha helices, and the beta sheets interact.
References
- ↑ Wu CC, Li TK, Farh L, Lin LY, Lin TS, Yu YJ, Yen TJ, Chiang CW, Chan NL. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science. 2011 Jul 22;333(6041):459-62. PMID:21778401 doi:10.1126/science.1204117
